Novo Nordisk (NOVOB DC) announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus, building on continued efforts to expand access

Novo Nordisk's announcement of a significant reduction in the US list price for Wegovy, Ozempic, and Rybelsus signals the company's continued commitment to enhancing patient access.

Newsquawk StaffPublished On the live feed at 9 more headlines followed before this page went public
Newsquawk headlinesUTC

US Trump Adminstration is to use a Pentagon-created AI model to set reference prices for critical minerals in a global trading block, according to sources; these include Antimony, Tungsten, Germanium and Gallium

EU Commission is reportedly on the 15th of April to propose legislation to phase out the remaining Russian oil imports, according to a draft document

Novo Nordisk (NOVOB DC) announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus, building on continued efforts to expand access

Fed's Goolsbee (2027 voter) optimistic there can be more rate cuts this year, but not until inflation is heading back to target

US BROKER MOVES: QCOM upgraded at Loop Capital and Wells Fargo; OWL downgraded at Deutsche Bank

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • New, lower list price of USD 675/month across Wegovy, Ozempic, and Rybelsus, effective January 1st, 2027.
  • These changes in list price do not have an impact on direct-to-patient, self-pay prices
  • Decision applies to all doses of these medicines.
Context

While this move does not affect direct-to-patient prices, it may pressure market dynamics and competitor pricing strategies ahead of the effective date. Traders should monitor how this impacts Novo Nordisk's share price and broader market sentiment regarding the pharmaceutical sector.

Related headlines

The whole workspace, free to try.

Try it free